Carbohydrate vaccines for the immunotherapy of cancer Journal Article


Author: Lloyd, K. O.
Article Title: Carbohydrate vaccines for the immunotherapy of cancer
Abstract: On the basis of the observation that tumor cells exhibit aberrant glycosylation, carbohydrate vaccines are being developed for the active immunotherapy of cancer. Potential targets include members of the ABH Lewis blood group family (e.g., Lewisy), members of the mucin core family (e.g., Tn, sialyl Tn and T-F) and gangliosides (e.g., GM2). Most studies have used glycoconjugate vaccines in which a synthetic oligosaccharide is coupled to a protein carrier, for example, KLH, but completely synthetic constructs are also being examined. Preclinical studies in mice have shown the effectiveness of some of these vaccines. Clinical studies are under way in a number of human cancers but the results are still being evaluated. © 2000 Prous Science.
Keywords: carrier protein; unclassified drug; clinical trial; review; drug efficacy; nonhuman; drug targeting; cancer immunotherapy; blood group abo system; drug synthesis; cancer vaccine; epitope; glycosylation; ganglioside gm2; tn antigen; carbohydrate; keyhole limpet hemocyanin; mucin; oligosaccharide; glycoconjugate; ganglioside; blood group lewis system; cancer; human; protein stn; protein tf
Journal Title: Drug News & Perspectives
Volume: 13
Issue: 8
ISSN: 0214-0934
Publisher: Prous Science  
Date Published: 2000-10-01
Start Page: 463
End Page: 470
Language: English
PROVIDER: scopus
PUBMED: 12937618
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Citation Impact
MSK Authors
  1. Kenneth O Lloyd
    163 Lloyd